$MTEK
Maris Tech Ltd. Stock $mtek

$mtek Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 20-F Financial Statement

#000121390023017628 Filed on March 06, 2023

Income Statement

Concept	2022 Q4	2022 Q2	2022 Q1
Revenue	$1.537M	$967.9K	$1.350M
YoY Change	-99.79%	-99.93%
Cost Of Revenue	$1.071M	$651.2K
YoY Change	-99.77%	-99.9%
Gross Profit	$466.0K	$316.8K
YoY Change	-99.84%	-99.95%
Gross Profit Margin	30.32%	32.73%
Selling, General & Admin	$1.488M	$1.957M
YoY Change	-99.69%	-99.44%
% of Gross Profit	319.34%	617.66%
Research & Development	$371.5K	$650.4K
YoY Change	-99.88%	-99.84%
% of Gross Profit	79.71%	205.32%
Depreciation & Amortization	$12.96K	$4.250K
YoY Change	-99.51%	-99.82%
% of Gross Profit	2.78%	1.34%
Operating Expenses	$1.860M	$2.607M
YoY Change	-99.76%	-99.65%
Operating Profit	-$1.394M	-$2.290M
YoY Change	-99.72%	-96.71%
Interest Expense	-$21.04K	$16.54K
YoY Change	-99.99%	-100.45%
% of Operating Profit
Other Income/Expense, Net		$16.54K
YoY Change
Pretax Income	-$1.415M	-$2.274M
YoY Change	-99.81%	-96.89%
Income Tax
% Of Pretax Income
Net Earnings	-$1.415M	-$2.274M
YoY Change	-99.81%	-96.89%
Net Earnings / Revenue	-92.04%	-234.9%
Basic Earnings Per Share
Diluted Earnings Per Share	-$0.18	-$321.6K
COMMON SHARES
Basic Shares Outstanding	7.999M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2022 Q4	2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$222.0K	$346.9K
YoY Change	-71.72%	-99.57%
Cash & Equivalents	$222.0K	$346.9K
Short-Term Investments
Other Short-Term Assets	$9.084M	$11.04M
YoY Change		-20.42%
Inventory	$981.7K	$533.2K
Prepaid Expenses
Receivables	$1.606M	$634.0K
Other Receivables	$359.6K	$579.7K
Total Short-Term Assets	$12.25M	$13.13M
YoY Change	-98.73%	-99.1%
LONG-TERM ASSETS
Property, Plant & Equipment	$283.8K	$770.0K
YoY Change	-98.28%	-95.89%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$190.3K	$192.4K
YoY Change	-99.98%	-99.95%
Total Long-Term Assets	$1.110M	$962.4K
YoY Change	-99.9%	-99.76%
TOTAL ASSETS
Total Short-Term Assets	$12.25M	$13.13M
Total Long-Term Assets	$1.110M	$962.4K
Total Assets	$13.36M	$14.10M
YoY Change	-99.34%	-99.24%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.083M	$493.1K
YoY Change	-99.77%	-99.88%
Accrued Expenses	$316.9K	$0.00
YoY Change	-99.94%	-100.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$10.58K
YoY Change	-100.0%	-100.0%
Total Short-Term Liabilities	$1.811M	$1.110M
YoY Change	-99.91%	-99.9%
LONG-TERM LIABILITIES
Long-Term Debt		$1.088M
YoY Change		-99.94%
Other Long-Term Liabilities	$867.9K	$929.0K
YoY Change	-99.86%	-99.82%
Total Long-Term Liabilities	$1.956M	$2.017M
YoY Change	-99.92%	-99.92%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.811M	$1.110M
Total Long-Term Liabilities	$1.956M	$2.017M
Total Liabilities	$3.767M	$3.127M
YoY Change	-99.91%	-99.91%
SHAREHOLDERS EQUITY
Retained Earnings	-$8.193M
YoY Change	81.89%
Common Stock	$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$9.597M	$10.97M
YoY Change
Total Liabilities & Shareholders Equity	$13.36M	$14.10M
YoY Change	-99.34%	-99.24%

Cashflow Statement

Concept	2022 Q4	2022 Q2
OPERATING ACTIVITIES
Net Income	-$1.415M	-$2.274M
YoY Change	-99.81%	-96.89%
Depreciation, Depletion And Amortization	$12.96K	$4.250K
YoY Change	-99.51%	-99.82%
Cash From Operating Activities	-$1.907M	-$2.950M
YoY Change	-98.37%	-99.61%
INVESTING ACTIVITIES
Capital Expenditures	$219.8K	-$64.74K
YoY Change	-154.94%	-99.14%
Acquisitions
YoY Change
Other Investing Activities	$2.002M	-$11.02M
YoY Change	-112.79%	89.81%
Cash From Investing Activities	$1.782M	-$11.09M
YoY Change	-111.1%	-17.1%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	14.37M
YoY Change	-100.0%	-98.34%
NET CHANGE
Cash From Operating Activities	-1.907M	-2.950M
Cash From Investing Activities	1.782M	-11.09M
Cash From Financing Activities	0.000	14.37M
Net Change In Cash	-124.9K	331.3K
YoY Change	-99.88%	-99.66%
FREE CASH FLOW
Cash From Operating Activities	-$1.907M	-$2.950M
Capital Expenditures	$219.8K	-$64.74K
Free Cash Flow	-$2.127M	-$2.885M
YoY Change	-98.18%	-99.62%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Document Type DocumentType	20-F
CY2022	dei	Document Registration Statement DocumentRegistrationStatement	false
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Document Shell Company Report DocumentShellCompanyReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-39957
CY2022	dei	Entity Registrant Name EntityRegistrantName	Maris-Tech Ltd.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	L3
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	2 Yitzhak Modai Street
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Rehovot
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	7608804
CY2022	dei	Entity Address Country EntityAddressCountry	IL
CY2022	dei	Security12b Title Security12bTitle	Ordinary Shares, no par value per share
CY2022	dei	Trading Symbol TradingSymbol	MTEK
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	7999216	shares
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Document Accounting Standard DocumentAccountingStandard	U.S. GAAP
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022	dei	Auditor Firm AuditorFirmId	1309
CY2022	dei	Auditor Name AuditorName	Kesselman & Kesselman
CY2022	dei	Auditor Location AuditorLocation	Tel Aviv, Israel
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	221961	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	785	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	9084082	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1606495	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	571482	usd
CY2022Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	359591	usd
CY2021Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	2873	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	981729	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	391484	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	12253858	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	966624	usd
CY2022Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	33569	usd
CY2021Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	48341	usd
CY2021Q4	us-gaap	Deferred Costs DeferredCosts	871171	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	283790	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	16511	usd
CY2022Q4	mtek	Severance Pay Deposits SeverancePayDeposits	156723	usd
CY2021Q4	mtek	Severance Pay Deposits SeverancePayDeposits	136620	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	635976	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	1110058	usd
CY2021Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	1072643	usd
CY2022Q4	us-gaap	Assets Assets	13363916	usd
CY2021Q4	us-gaap	Assets Assets	2039267	usd
CY2021Q4	us-gaap	Debt Current DebtCurrent	410324	usd
CY2022Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	1083345	usd
CY2021Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	463653	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	727560	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	791038	usd
CY2021Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	296459	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1810905	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1961474	usd
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	744769	usd
CY2022Q4	us-gaap	Due To Related Parties Noncurrent DueToRelatedPartiesNoncurrent	1088250	usd
CY2021Q4	us-gaap	Due To Related Parties Noncurrent DueToRelatedPartiesNoncurrent	1088250	usd
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	351845	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	442166	usd
CY2022Q4	mtek	Accrued Severance Pay AccruedSeverancePay	425742	usd
CY2021Q4	mtek	Accrued Severance Pay AccruedSeverancePay	272509	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	1956158	usd
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	2457373	usd
CY2022Q4	us-gaap	Liabilities Liabilities	3767063	usd
CY2021Q4	us-gaap	Liabilities Liabilities	4418847	usd
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	12500000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7999216	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7999216	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3085000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3085000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	489812	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	489812	shares
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	17789380	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2124601	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-8192527	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-4504181	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	9596853	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-2379580	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	13363916	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2039267	usd
CY2022	us-gaap	Revenues Revenues	2504896	usd
CY2021	us-gaap	Revenues Revenues	2075755	usd
CY2020	us-gaap	Revenues Revenues	987883	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	1722104	usd
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	1106447	usd
CY2020	us-gaap	Cost Of Revenue CostOfRevenue	500696	usd
CY2022	us-gaap	Gross Profit GrossProfit	782792	usd
CY2021	us-gaap	Gross Profit GrossProfit	969308	usd
CY2020	us-gaap	Gross Profit GrossProfit	487187	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1021869	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	706021	usd
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	781417	usd
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	604114	usd
CY2021	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	241114	usd
CY2020	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	22551	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2840660	usd
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	595074	usd
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	74169	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	4466643	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	1542209	usd
CY2020	us-gaap	Operating Expenses OperatingExpenses	878138	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	3683851	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	572901	usd
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	390951	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	4495	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	251323	usd
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	249392	usd
CY2022	us-gaap	Profit Loss ProfitLoss	3688346	usd
CY2021	us-gaap	Profit Loss ProfitLoss	824224	usd
CY2020	us-gaap	Profit Loss ProfitLoss	640343	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.49
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.24
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.26
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7528038	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3464470	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2483988	shares
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-2491370	usd
CY2020	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1078808	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-640343	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-2601149	usd
CY2021	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	1045793	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-824224	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-2379580	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	15176584	usd
CY2022	us-gaap	Reclassifications Of Temporary To Permanent Equity ReclassificationsOfTemporaryToPermanentEquity	412299	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	75896	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-3688346	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	9596853	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-3688346	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-824224	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-640343	usd
CY2022	us-gaap	Depreciation Depreciation	17211	usd
CY2021	us-gaap	Depreciation Depreciation	5056	usd
CY2020	us-gaap	Depreciation Depreciation	3525	usd
CY2022	mtek	Revaluation Of Warrants RevaluationOfWarrants	60454	usd
CY2021	mtek	Revaluation Of Warrants RevaluationOfWarrants	77551	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	75896	usd
CY2022	mtek	Increase Decreasein Exchange Differences IncreaseDecreaseinExchangeDifferences	133816	usd
CY2021	mtek	Increase Decreasein Exchange Differences IncreaseDecreaseinExchangeDifferences	39731	usd
CY2020	mtek	Increase Decreasein Exchange Differences IncreaseDecreaseinExchangeDifferences	-47055	usd
CY2020	mtek	Interest On Shareholders Loan InterestOnShareholdersLoan	1700	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	153233	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	55052	usd
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	41179	usd
CY2022	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	1035013	usd
CY2021	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	443944	usd
CY2020	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-108319	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	356718	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	95	usd
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-4632	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	590245	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	140417	usd
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-102711	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	619692	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	213859	usd
CY2020	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-61368	usd
CY2022	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	20625	usd
CY2021	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	221891	usd
CY2020	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-25900	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4857027	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-875002	usd
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-418490	usd
CY2022	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	12500000	usd
CY2022	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	3500000	usd
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	20103	usd
CY2021	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	21457	usd
CY2020	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	27502	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	284490	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7967	usd
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6041	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-9304593	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-29424	usd
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-33543	usd
CY2022	us-gaap	Proceeds From Repayments Of Short Term Debt ProceedsFromRepaymentsOfShortTermDebt	-410324	usd
CY2021	us-gaap	Proceeds From Repayments Of Short Term Debt ProceedsFromRepaymentsOfShortTermDebt	-56638	usd
CY2020	us-gaap	Proceeds From Repayments Of Short Term Debt ProceedsFromRepaymentsOfShortTermDebt	353138	usd
CY2021	mtek	Proceeds From Loans Received From Shareholders ProceedsFromLoansReceivedFromShareholders	199547	usd
CY2020	mtek	Proceeds From Loans Received From Shareholders ProceedsFromLoansReceivedFromShareholders	250853	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	17824992	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1500000	usd
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	2101875	usd
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	179913	usd
CY2021	us-gaap	Proceeds From Issuance Of Other Long Term Debt ProceedsFromIssuanceOfOtherLongTermDebt	183038	usd
CY2022	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	744769	usd
CY2021	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	125247	usd
CY2020	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	148631	usd
CY2022	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	200000	usd
CY2021	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	621607	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	14368024	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	899180	usd
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	455360	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	206404	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-5245	usd
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	3327	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	49126	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	54371	usd
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	51044	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	255530	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	49126	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	54371	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	16882	usd
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	15372	usd
CY2020	us-gaap	Income Taxes Paid IncomeTaxesPaid	56148	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	8686	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	154	usd
CY2020	us-gaap	Interest Paid Net InterestPaidNet	4	usd
CY2020	mtek	Conversion Of Longterm Liabilities To Shareholders To Ordinary Shares ConversionOfLongtermLiabilitiesToShareholdersToOrdinaryShares	1078808	usd
CY2021	mtek	Noncash Deferred Issuance Cost NoncashDeferredIssuanceCost	249564	usd
CY2022	us-gaap	Stock Issued1 StockIssued1	412299	usd
CY2022	mtek	Working Capital Deficit WorkingCapitalDeficit	10400000	usd
CY2021	mtek	Working Capital Deficit WorkingCapitalDeficit	1000000	usd
CY2022Q4	us-gaap	Cumulative Earnings Deficit CumulativeEarningsDeficit	8200000	usd
CY2021Q4	us-gaap	Cumulative Earnings Deficit CumulativeEarningsDeficit	4500000	usd
CY2022	mtek	Operating Activity OperatingActivity	4900000	usd
CY2021	mtek	Operating Activity OperatingActivity	900000	usd
CY2022Q1	us-gaap	Preferred Units Issued PreferredUnitsIssued	4244048	shares
CY2022Q1	mtek	Warrants To Purchase Ordinary Shares WarrantsToPurchaseOrdinaryShares	4244048	shares
CY2022Q1	us-gaap	Underwriting Income Loss UnderwritingIncomeLoss	1350000	usd
CY2022Q1	us-gaap	Other Ownership Interests Offering Costs OtherOwnershipInterestsOfferingCosts	1350000	usd
CY2022Q1	mtek	Repaid Liabilities RepaidLiabilities	1400000	usd
CY2022Q2	mtek	Repaid Liabilities RepaidLiabilities	1400000	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="text-align: left; width: 0%"/><td style="width: 0.5in; text-align: left"><b>B.</b></td><td style="text-align: left"><b>Estimates and assumptions</b></td> </tr></table><p style="text-align: left; margin-top: 0; margin-bottom: 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left">The preparation of the financial statements in conformity with U.S GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during reported period. Actual results may differ from those estimates. As applicable for these financial statements, the most significant estimates and assumptions related to revenue recognition, and valuation of inventories.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2021	us-gaap	Related Parties Amount In Cost Of Sales RelatedPartiesAmountInCostOfSales	871171	usd
CY2021Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	20758	usd
CY2020Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	9879	usd
CY2019Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	8930	usd
CY2022	mtek	Cost Incurred CostIncurred	-3220	usd
CY2021	mtek	Cost Incurred CostIncurred	-5850	usd
CY2022	mtek	Expense Recognized ExpenseRecognized	7511	usd
CY2021	mtek	Expense Recognized ExpenseRecognized	16729	usd
CY2020	mtek	Expense Recognized ExpenseRecognized	949	usd
CY2022Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	25049	usd
CY2021Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	20758	usd
CY2020Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	9879	usd
CY2022	mtek	Ultimate Settlement UltimateSettlement	0.50	pure
CY2022Q4	mtek	Severance Pay Expenses SeverancePayExpenses	61169	usd
CY2021Q4	mtek	Severance Pay Expenses SeverancePayExpenses	31356	usd
CY2020Q4	mtek	Severance Pay Expenses SeverancePayExpenses	22247	usd
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: justify"> <td style="text-align: left; width: 0in"/><td style="width: 0.5in; text-align: left"><b>R.</b></td><td style="text-align: left"><b>Concentrations of credit or business risk</b></td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash equivalents, bank deposits, trade receivables and trade payables.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">Cash equivalents and bank deposits are invested mainly in NIS and U.S. dollars with major banks in Israel. Management believes that the financial institutions that hold the Company’s investments are financially sound and, accordingly, minimal credit risk exists with respect to these investments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">Most of the Company’s trade receivables are derived from sales to large and financially secure organizations. In determining the adequacy of the allowance, management bases its opinion, inter alia, on the estimated risks, current market conditions and in reliance on available information with respect to the debtor’s financial position. See Note 10 for a discussion of the Company’s major customers.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.25in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">The Company acquires certain component parts for its products from market leading suppliers that are single source manufacturers. In order to mitigate the risk and as a redundant solution, the Company designs similar products based on component parts from different suppliers.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt"> </p>
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	221961	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	785	usd
CY2022Q4	us-gaap	Certificates Of Deposit At Carrying Value CertificatesOfDepositAtCarryingValue	33569	usd
CY2021Q4	us-gaap	Certificates Of Deposit At Carrying Value CertificatesOfDepositAtCarryingValue	48341	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	255530	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	49126	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	530444	usd
CY2022Q4	us-gaap	Federal Home Loan Bank Advances Interest Rate FederalHomeLoanBankAdvancesInterestRate	0.011	pure
CY2021Q4	us-gaap	Federal Home Loan Bank Advances Interest Rate FederalHomeLoanBankAdvancesInterestRate	0.003	pure
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	551774	usd
CY2021Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	212736	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	429955	usd
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	178748	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	981729	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	391484	usd
CY2022	us-gaap	Other Expenses OtherExpenses	11856	usd
CY2021	us-gaap	Other Expenses OtherExpenses	0	usd
CY2020	us-gaap	Other Expenses OtherExpenses	22957	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	533673	usd
CY2022Q4	mtek	Customer Advances CustomerAdvances	144076	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	43089	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	14916	usd
CY2022Q4	us-gaap	Property Plant And Equipment Other PropertyPlantAndEquipmentOther	148712	usd
CY2022Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	125282	usd
CY2021Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	17684	usd
CY2022	us-gaap	Lease Cost LeaseCost	317083	usd
CY2021	us-gaap	Lease Cost LeaseCost	32600	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	33293	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	16089	usd
CY2022Q4	us-gaap	Property Plant And Equipment Other Net PropertyPlantAndEquipmentOtherNet	283790	usd
CY2021Q4	us-gaap	Property Plant And Equipment Other Net PropertyPlantAndEquipmentOtherNet	16511	usd
CY2022	us-gaap	Depreciation Depreciation	17211	usd
CY2021	us-gaap	Depreciation Depreciation	5056	usd
CY2020	us-gaap	Depreciation Depreciation	3525	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	357188	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	191004	usd
CY2022Q4	us-gaap	Extended Product Warranty Accrual Current ExtendedProductWarrantyAccrualCurrent	25049	usd
CY2021Q4	us-gaap	Extended Product Warranty Accrual Current ExtendedProductWarrantyAccrualCurrent	20758	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	172818	usd
CY2022Q4	mtek	Government Authorities GovernmentAuthorities	28429	usd
CY2021Q4	mtek	Government Authorities GovernmentAuthorities	45603	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	727560	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	791038	usd
CY2022	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	391916	shares
CY2022	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	111371	usd
CY2022	mtek	Total Research And Development Income TotalResearchAndDevelopmentIncome	345347	ils
CY2022	mtek	Total Research And Development Income TotalResearchAndDevelopmentIncome	98138	usd
CY2021Q4	mtek	Loan Amount LoanAmount	200000	usd
CY2021Q4	us-gaap	Short Term Debt Interest Rate Increase ShortTermDebtInterestRateIncrease	0.04	pure
CY2021Q4	us-gaap	Loans Payable To Bank Current LoansPayableToBankCurrent	1105438	usd
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	360669	usd
CY2021Q4	us-gaap	Other Long Term Debt OtherLongTermDebt	744769	usd
CY2022	us-gaap	Loan Portfolio Expense LoanPortfolioExpense	11244	usd
CY2021	us-gaap	Loan Portfolio Expense LoanPortfolioExpense	50582	usd
CY2020	us-gaap	Loan Portfolio Expense LoanPortfolioExpense	47560	usd
	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	1200000	usd
CY2021Q4	us-gaap	Loans Payable To Bank LoansPayableToBank	410324	usd
CY2021Q2	us-gaap	Line Of Credit LineOfCredit	400000	ils
CY2021Q2	us-gaap	Line Of Credit LineOfCredit	121501	usd
CY2022Q4	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	0	ils
CY2021Q4	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	154427	ils
CY2022Q4	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	49655	usd
CY2021Q4	us-gaap	Deferred Compensation Arrangement With Individual Cash Award Granted Amount DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount	1600000	usd
CY2022Q4	us-gaap	Grants Receivable Current GrantsReceivableCurrent	285204	usd
CY2022	us-gaap	Payments For Royalties PaymentsForRoyalties	7301	usd
CY2022	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	1314024	shares
CY2022Q4	us-gaap	Other Receivables Gross Current OtherReceivablesGrossCurrent	373408	usd
CY2022Q4	us-gaap	Grants Receivable GrantsReceivable	246449	usd
CY2022	us-gaap	Revenues Revenues	2504896	usd
CY2021	us-gaap	Revenues Revenues	2075755	usd
CY2020	us-gaap	Revenues Revenues	987883	usd
CY2022Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	237982	usd
CY2022	mtek	Unsatisfied Performance Obligation UnsatisfiedPerformanceObligation	90122	usd
CY2021	mtek	Unsatisfied Performance Obligation UnsatisfiedPerformanceObligation	130000	usd
CY2022	us-gaap	Revenues Net Of Interest Expense RevenuesNetOfInterestExpense	2504937	usd
CY2021	us-gaap	Revenues Net Of Interest Expense RevenuesNetOfInterestExpense	2075755	usd
CY2020	us-gaap	Revenues Net Of Interest Expense RevenuesNetOfInterestExpense	987883	usd
CY2022	us-gaap	Net Income Loss Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossAttributableToNonredeemableNoncontrollingInterest	3688346	usd
CY2021	us-gaap	Net Income Loss Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossAttributableToNonredeemableNoncontrollingInterest	824224	usd
CY2020	us-gaap	Net Income Loss Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossAttributableToNonredeemableNoncontrollingInterest	640343	usd
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7528038	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3464470	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2483988	shares
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.49
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.24
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.26
CY2022Q4	mtek	Options To Purchase Ordinary Share OptionsToPurchaseOrdinaryShare	205269	shares
CY2022Q4	mtek	Warrant Shares WarrantShares	5001432	shares
CY2021Q4	mtek	Warrant Shares WarrantShares	379772	shares
CY2022Q4	mtek	Total Potentially Dilutive Securitie TotalPotentiallyDilutiveSecuritie	5206700	shares
CY2021Q4	mtek	Total Potentially Dilutive Securitie TotalPotentiallyDilutiveSecuritie	379772	shares
CY2022Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	4.2
CY2022Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	4.199
CY2022Q1	mtek	Pre Funded Warrants PreFundedWarrants	488324	shares
CY2022Q1	us-gaap	Share Price SharePrice	0.001
CY2022Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	185023	shares
CY2022Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	5.25
CY2022Q1	us-gaap	Other Underwriting Expense OtherUnderwritingExpense	1350000	usd
CY2022Q1	us-gaap	Deferred Offering Costs DeferredOfferingCosts	1350000	usd
CY2022	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	489812	shares
CY2022Q4	mtek	Underwriters Warrants UnderwritersWarrants	185023	shares
CY2022	mtek	Fair Value Adjustment Of Underwriters FairValueAdjustmentOfUnderwriters	199825	usd
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	400472	shares
CY2022Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	4.2
CY2022Q4	mtek	Provision Of Warrants ProvisionOfWarrants	75000	usd
CY2022Q3	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	180409	shares
CY2022Q3	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	180356	shares
CY2022Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	118	usd
CY2021Q1	mtek	Aggregate Of Preferred Shares AggregateOfPreferredShares	489812	shares
CY2021Q1	mtek	Aggregate Gross Proceed AggregateGrossProceed	1500000	usd
CY2021Q1	mtek	Warrants Received WarrantsReceived	1	pure
CY2021Q1	mtek	Purchase Of Ordinary Share PurchaseOfOrdinaryShare	1	pure
CY2021Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	6.1248
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	274294	usd
CY2021Q1	mtek	Percentage Of Gross Proceeds PercentageOfGrossProceeds	0.05	pure
CY2022	mtek	Consideration Amount ConsiderationAmount	75000	usd
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.2
CY2022	mtek	Warrants Issued WarrantsIssued	28194	usd
CY2021Q3	us-gaap	Conversion Of Stock Description ConversionOfStockDescription	the Company’s general meeting of shareholders approved a reverse share split of the Ordinary Shares and the Preferred Shares, at a ratio of 4:1 (four-to-one), so that holders of Ordinary Shares and Preferred Shares will receive one Ordinary Share and one Preferred Share, respectively, for every four Ordinary Shares and Preferred Shares held as of such date rounded to the nearest number (with 0.5 share rounded up), and to adopt an amendment to the Company’s Articles of Association to effectuate such reverse stock split.
CY2022Q2	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	1000000	usd
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Method Used ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed	$274,294
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	77551	usd
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.5582	pure
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0169	pure
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y2M8D
CY2022Q1	us-gaap	Net Asset Value Per Share NetAssetValuePerShare	3.12
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	6.1248
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	60454	usd
CY2021Q3	mtek	Aggregate Of Ordinary Shares AggregateOfOrdinaryShares	285422	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Description ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription	Out of the total amount of 285,422, options to purchase an aggregate of 201,427 Ordinary Shares were approved on June 27, 2021 and options to purchase an aggregate of 83,995 Ordinary Shares were approved during July 2021.
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Description ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription	the Company issued the following options under the SOP: (i) options to purchase an aggregate of 71,496 Ordinary Shares to the former chairman of the Company’s board of directors, which options were exercisable for a period of five years from their date of issuance, at a price of $4.20 per Ordinary Share, and vest 8.33% at the end of each three month period of continuous services to the Company. The fair value of this grant was $90,085 calculated using the Black Scholes model; (ii) options to purchase an aggregate of 10,000 Ordinary Shares and options to purchase an aggregate of 2,500 Ordinary Shares to two of the Company’s directors, which options are exercisable for a period of five years from their date of issuance, at a price of $4.20 per Ordinary Share, and vest 6.25% at the end of each three month period of continuous services to the Company. The fair value of this grant was $15,750 calculated using the Black Scholes model; and (iii) options to purchase an aggregate of 169,588 Ordinary Shares to certain employees and consultants, which options are exercisable for a period of five years from their date of issuance, at a price of $4.20 per Ordinary Share, and will vest 50% on February 4, 2024 and thereafter 6.25% every three months period of continuous services to the Company. The fair value of this grant was $191,634 calculated using the Black Scholes model. Upon the end of term of the service agreement with Mr. Joseph Weiss in December 2022, options to purchase an aggregate of 53,622 Ordinary Shares were forfeited and returned to the pool.
CY2022Q2	mtek	Vest Percentage VestPercentage	0.0625	pure
CY2022Q2	mtek	Fair Value Grant Amount FairValueGrantAmount	10204	usd
CY2022Q4	mtek	Vest Percentage VestPercentage	0.0625	pure
CY2022	mtek	Fair Value Grant Amount FairValueGrantAmount	188	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	287922	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	53622	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	4.2
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	4.2
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	234300	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	20218	shares
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	4.2
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P0Y8M12D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.07
CY2022	mtek	Unvested Options UnvestedOptions	214082	usd
CY2022	mtek	Unvested Options Cost UnvestedOptionsCost	168893	usd
CY2022	us-gaap	Insured Financial Obligations With Credit Deterioration Remaining Weighted Average Contract Period InsuredFinancialObligationsWithCreditDeteriorationRemainingWeightedAverageContractPeriod	P3Y3M
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.23	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.23	pure
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	1218869	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	675604	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	189856	usd
CY2021Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	181964	usd
CY2022Q4	mtek	Provisions For Warranty ProvisionsForWarranty	5761	usd
CY2021Q4	mtek	Provisions For Warranty ProvisionsForWarranty	4774	usd
CY2022Q4	mtek	Provision For Vacation And Convalescence ProvisionForVacationAndConvalescence	49850	usd
CY2021Q4	mtek	Provision For Vacation And Convalescence ProvisionForVacationAndConvalescence	20575	usd
CY2022Q4	mtek	Provision For Severance ProvisionForSeverance	62060	usd
CY2021Q4	mtek	Provision For Severance ProvisionForSeverance	31254	usd
CY2022Q4	mtek	Operating Lease Right Of Use Assets OperatingLeaseRightOfUseAssets	134836	usd
CY2022Q4	mtek	Issuance Cost IssuanceCost	381090	usd
CY2022Q4	mtek	Operating Lease Liabilities01 OperatingLeaseLiabilities01	134836	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1907486	usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	914171	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	914171	usd
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	636462	usd
CY2022	us-gaap	Valuation Allowance For Impairment Of Recognized Servicing Assets Provisions ValuationAllowanceForImpairmentOfRecognizedServicingAssetsProvisions	993315	usd
CY2021	us-gaap	Valuation Allowance For Impairment Of Recognized Servicing Assets Provisions ValuationAllowanceForImpairmentOfRecognizedServicingAssetsProvisions	277709	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1907486	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	914171	usd
CY2021	mtek	Conversion Of Longterm Liabilities To Shareholders To Ordinary Shares ConversionOfLongtermLiabilitiesToShareholdersToOrdinaryShares		usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	5200000	usd
CY2021Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	2400000	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	126169	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	114749	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	205593	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y8M12D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0508	pure
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	147338	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	134701	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	132174	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	132174	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	110145	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	656532	usd
CY2022Q4	mtek	Imputed Interest ImputedInterest	-70290	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	586242	usd
CY2022	mtek	Noncash Deferred Issuance Cost NoncashDeferredIssuanceCost		usd
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.26
CY2021Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	114085	usd
CY2021Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	114085	usd
CY2021Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	99786	usd
CY2021Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	96926	usd
CY2021Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	96926	usd
CY2021Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	80772	usd
CY2020Q4	us-gaap	Due From Officers Or Stockholders Current DueFromOfficersOrStockholdersCurrent	1088703	usd
CY2021Q2	us-gaap	Related Party Transaction Description Of Transaction RelatedPartyTransactionDescriptionOfTransaction	the Company entered into a loan facility agreement (as amended on June 30, 2021 the “Loan Facility Agreement”), effective as of January 1, 2021, with Mr. Bar and Mr. Gottlieb. Pursuant to the Loan Facility Agreement, the outstanding amount under the Loan Facility Agreement to be paid to Mr. Bar in a total amount of approximately NIS 2,459,959 (approximately $770,879) and to Mr. Gottlieb, in a total amount of approximately NIS 1,020,347 (approximately $317,371), bear no interest and shall be due and payable in 24 equal monthly payments, commencing on the second anniversary following completion of an initial public offering. Pursuant to the Loan Facility Agreement, if an initial public offering is not completed by December 31, 2021, then the outstanding amount shall be repaid pursuant to the available free cash of the Company, taking into account expected expenditures in the three months following partial or full payment, and in any event not prior to December 31, 2022. The Company also agreed to reimburse Mr. Bar and Mr. Gottlieb for any costs and expenses incurred in connection with the enforcement of the Loan Facility Agreement, if required. The agreement was accounted for as a modification with no change to the book value of the loan. As of December 31, 2022 the outstanding amount under the Loan Facility Agreement is $1,088,250. The loans were classified within long term liabilities.
CY2022Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	0	usd
CY2021Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	96320	usd
CY2021Q4	us-gaap	Related Party Transaction Due From To Related Party RelatedPartyTransactionDueFromToRelatedParty	96320	usd
CY2021	mtek	Short Term Liabilities ShortTermLiabilities	200000	usd
CY2022	mtek	Longterm Loans Due To Shareholders LongtermLoansDueToShareholders	1088250	usd
CY2021	mtek	Longterm Loans Due To Shareholders LongtermLoansDueToShareholders	1088250	usd
CY2022	us-gaap	Interest Expense InterestExpense	30684	usd
CY2022Q4	us-gaap	Due From Related Parties DueFromRelatedParties	258397	usd
CY2021	us-gaap	Related Party Transaction Purchases From Related Party RelatedPartyTransactionPurchasesFromRelatedParty	1501	usd
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.49
CY2021Q4	mtek	Options To Purchase Ordinary Share OptionsToPurchaseOrdinaryShare		shares
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2021Q4	mtek	Operating Lease Right Of Use Assets OperatingLeaseRightOfUseAssets		usd
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments		usd
CY2022Q4	us-gaap	Deferred Costs DeferredCosts		usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset		usd
CY2022Q4	us-gaap	Debt Current DebtCurrent		usd
CY2022Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent		usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent		usd
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent		usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue		usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue		usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized		shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1250000	shares
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.24
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.26
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.49
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised		usd
CY2022	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue		usd
CY2020	mtek	Revaluation Of Warrants RevaluationOfWarrants		usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation		usd
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation		usd
CY2022	mtek	Interest On Shareholders Loan InterestOnShareholdersLoan		usd
CY2021	mtek	Interest On Shareholders Loan InterestOnShareholdersLoan		usd
CY2020	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments		usd
CY2021	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments		usd
CY2020	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments		usd
CY2022	mtek	Proceeds From Loans Received From Shareholders ProceedsFromLoansReceivedFromShareholders		usd
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2020	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts		usd
CY2022	us-gaap	Proceeds From Issuance Of Other Long Term Debt ProceedsFromIssuanceOfOtherLongTermDebt		usd
CY2020	us-gaap	Proceeds From Issuance Of Other Long Term Debt ProceedsFromIssuanceOfOtherLongTermDebt		usd
CY2021	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt		usd
CY2020	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt		usd
CY2022	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts		usd
CY2020Q4	mtek	Options To Purchase Ordinary Share OptionsToPurchaseOrdinaryShare		shares
CY2021Q4	mtek	Operating Lease Liabilities01 OperatingLeaseLiabilities01		usd
CY2020	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts		usd
CY2022	mtek	Conversion Of Longterm Liabilities To Shareholders To Ordinary Shares ConversionOfLongtermLiabilitiesToShareholdersToOrdinaryShares		usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2021Q4	us-gaap	Property Plant And Equipment Other PropertyPlantAndEquipmentOther		usd
CY2020Q4	mtek	Warrant Shares WarrantShares		shares
CY2021Q4	mtek	Customer Advances CustomerAdvances		usd
CY2021Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent		usd
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2483988	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3464470	shares
CY2020	mtek	Noncash Deferred Issuance Cost NoncashDeferredIssuanceCost		usd
CY2020Q4	mtek	Total Potentially Dilutive Securitie TotalPotentiallyDilutiveSecuritie		shares
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.24
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7528038	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber		shares
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022	mtek	Short Term Liabilities ShortTermLiabilities		usd
CY2021	us-gaap	Interest Expense InterestExpense		usd
CY2021Q4	us-gaap	Due From Related Parties DueFromRelatedParties		usd
CY2022	us-gaap	Related Party Transaction Purchases From Related Party RelatedPartyTransactionPurchasesFromRelatedParty		usd
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001872964

Files In Submission

Name	View Source	Status
mtek-20221231_cal.xml	Edgar Link	unprocessable
mtek-20221231_def.xml	Edgar Link	unprocessable
0001213900-23-017628-index-headers.html	Edgar Link	pending
0001213900-23-017628-index.html	Edgar Link	pending
0001213900-23-017628.txt	Edgar Link	pending
0001213900-23-017628-xbrl.zip	Edgar Link	pending
ex15-1_001.jpg	Edgar Link	pending
ex4-5_001.jpg	Edgar Link	pending
ex4-5_002.jpg	Edgar Link	pending
ex4-5_003.jpg	Edgar Link	pending
f20f2022ex12-1_maristechltd.htm	Edgar Link	pending
f20f2022ex12-2_maristechltd.htm	Edgar Link	pending
f20f2022ex13-1_maristechltd.htm	Edgar Link	pending
f20f2022ex13-2_maristechltd.htm	Edgar Link	pending
f20f2022ex15-1_maristechltd.htm	Edgar Link	pending
f20f2022ex2-5_maristechltd.htm	Edgar Link	pending
f20f2022ex4-1_maristechltd.htm	Edgar Link	pending
f20f2022ex4-5_maristechltd.htm	Edgar Link	pending
f20f2022_maristechltd.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
f20f2022_maristechltd_htm.xml	Edgar Link	completed
image_002.jpg	Edgar Link	pending
image_003.jpg	Edgar Link	pending
image_004.jpg	Edgar Link	pending
image_005.jpg	Edgar Link	pending
image_006.jpg	Edgar Link	pending
image_007.jpg	Edgar Link	pending
image_008.jpg	Edgar Link	pending
image_009.jpg	Edgar Link	pending
image_010.jpg	Edgar Link	pending
image_011.jpg	Edgar Link	pending
image_012.jpg	Edgar Link	pending
image_013.jpg	Edgar Link	pending
image_014.jpg	Edgar Link	pending
image_015.jpg	Edgar Link	pending
image_016.jpg	Edgar Link	pending
image_017.jpg	Edgar Link	pending
image_018.jpg	Edgar Link	pending
image_019.jpg	Edgar Link	pending
image_020.jpg	Edgar Link	pending
image_021.jpg	Edgar Link	pending
image_022.jpg	Edgar Link	pending
image_023.jpg	Edgar Link	pending
image_024.jpg	Edgar Link	pending
image_025.jpg	Edgar Link	pending
image_026.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mtek-20221231.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
mtek-20221231_lab.xml	Edgar Link	unprocessable
mtek-20221231_pre.xml	Edgar Link	unprocessable
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MTEK
Maris Tech Ltd. Stock $mtek

2022 Q4 Form 20-F Financial Statement

#000121390023017628 Filed on March 06, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MTEK Maris Tech Ltd. Stock $mtek

2022 Q4 Form 20-F Financial Statement

#000121390023017628 Filed on March 06, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MTEK
Maris Tech Ltd. Stock $mtek